Literature DB >> 12390121

Intraocular pressure and progression of visual field damage.

B Brogliatti1, R Rigault, L Palanza, E Savio, T Rolle, A Fea, S Boggio Merlo.   

Abstract

Contradicting results concerning IOP control and visual field deterioration are presented. Some of these inconsistencies may be due to the statistical method of analysis. Sixty POAG patients with a perimetric follow-up over 3 years were selected. Mean and maximum IOPs were considered during the same period. The patients were divided into two groups according to the IOP control (well controlled or poorly controlled). Visual field progression was defined as a reduction in sensitivity over the fifth percentile in more than four points. Mean IOPs were not significantly different in the group of patients with a visual field deterioration compared to the stable ones, but the percentage of patients with a visual field deterioration was significantly higher in patients with higher IOPs. This holds especially true if IOP below 16 mmHg (G) is considered the 'target pressure'. IOP reduction seems to play an essential role in visual field progression. In glaucomatous patients, a strict (<16 mmHg (G)) might be necessary.

Entities:  

Mesh:

Year:  2002        PMID: 12390121     DOI: 10.1034/j.1600-0420.80.s236.15.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand Suppl        ISSN: 1395-3931


  2 in total

1.  Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: A prospective, open-label, randomized, two-arm, parallel-group study.

Authors:  Michele Vetrugno; Nicola Cardascia; Francesco Cantatore; Carlo Sborgia
Journal:  Curr Ther Res Clin Exp       Date:  2004-11

2.  Comparison of intraocular pressure fluctuations measured by goldmann applanation tonometer and pulsatile ocular blood flow analyser.

Authors:  Ingrida Januleviciene; Loreta Kuzmiene; Ieva Sliesoraityte
Journal:  Int J Biomed Sci       Date:  2006-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.